A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 344 participants.

Also called NCT04955834

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 344 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04955834
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04955834. Randomized; no masking; primary purpose treatment. Start 2021-07-27 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Study of Insulin Degludec Injection in Subjects With Type 2 Diabetes
Intervention (Drug)
Insulin degludec injection
Intervention (Drug)
Tresiba®
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04955834
Content hash
1b40fd6c7064f2eec18dfd9717ba790bf6639e60ec37d91ae2b5f216d78178af